出错

• Error translating Menus - missing currentLangMenuItems

• Sep 10 2012 NeoStem Subsidiary, Amorcyte, Announces Significant Expansion in its Claims Granted to Protect the Use of CD34+ Cells
• Sep 5 2012 Progenitor Cell Therapy, a NeoStem Company, Invited to Present at Two Conferences in September
• Sep 4 2012 NeoStem to Present at Three Investor Conferences in September
• Aug 15 2012 NeoStem Reports Data Safety Monitoring Board Recommends Continuation of PreSERVE AMI Phase 2 Trial
• Aug 14 2012 NeoStem Announces Quarterly Results and Business Update
• Jul 16 2012 NeoStem's Subsidiary, Progenitor Cell Therapy, and SOTIO Enter Into a Phase 3 Manufacturing Services Agreement
• Jul 10 2012 NeoStem to Present at the Seventh Annual JMP Securities Healthcare Conference
• Jul 9 2012 NeoStem CEO's Letter to Shareholders
• Jun 25 2012 NeoStem Awarded NIAID Research Grant for the Development of VSEL Technology for Radiation Exposure
• Jun 20 2012 NeoStem Announces Webcasting for the Marcum MicroCap Conference on June 20
• Jun 18 2012 NeoStem Signs a Definitive Agreement to Divest its 51% Ownership Interest in Suzhou Erye
• May 31 2012 NeoStem to Present at Six Conferences in June
• May 11 2012 NeoStem Reports First Quarter 2012 Results and Provides Business Update
• Apr 18 2012 NeoStem to Present at BioCentury Future Leaders in the Biotech Industry Conference
• Apr 11 2012 NeoStem Announces the Addition of Jonathan Sackner-Bernstein, MD, Past FDA Official, as Vice President, Clinical Development and Regulatory Affairs
• Apr 5 2012 NeoStem Closes Public Offering for $6,800,000 in Gross Proceeds
• Mar 29 2012 NeoStem Announces Pricing of Public Offering for $6,000,000 in Gross Proceeds
• Mar 28 2012 NeoStem Announces Proposed Public Offering of Common Stock and Warrants
• Mar 20 2012 NeoStem Provides Updates and Reports Year End Results
• Mar 2 2012 NeoStem Announces Participation in Two March Conferences

< 上页 | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 下页 >